

### Effect of Chromium Piclonate versus L-Carnitine on High fat Diet Induced in rats

Hanan Hosny Hanna<sup>1</sup> and Hassan Rania<sup>2</sup>

<sup>1</sup> Lecturer of Chemical Pathology, Physical therapy, Pharos University of Alexandria (PUA)<sup>2</sup> Lecturer of Biochemistry, Physical therapy, Pharos University of Alexandria (PUA).

Abstract: Introduction: The global prevalence of overweight and obesity is increasing rapidly worldwide among all ages. Several pharmacological agents such as insulin-sensitizing agents may be used to reduce or control the body weight and obesity. Obviously the need for natural supplements to decrease weight and help correction of some of complication became a very strong world need. This study try to show the effect of two natural product (LCarntine, Chromium Piclonate). Methodology: Male albino rats (n = 60) there were divided into three groups: control group (rats were fed a standard diet, Group I; rats were fed a high-fat diet for 60 days than followed with L-carnitine for 60 days, while group II; rats were fed a high-fat diet for 60 days than followed with Chromium Picolonate (Cr Pi) for 60 days. Results: As for Fasting blood sugar (FBS), there was statically significantly lower values (SD=84.3±3.7, P< 0.001) between group II Chromium group (Cr gp) over group I (L- carnitinegroup) after administration of drug. Regarding Hepatic enzymes; alanine aminotransferease (ALT) showed a statistically significantly lower values (P< 0.001) between Group II (82.8±3.7) over Group I (94.8±3.6) after administration of drugs. While total cholesterol and triglycerides showed statistically significant lower values in group II over group I. Also low density lipids (LDL) gp showed a statistically significant lowering effect [246.5±11.7], (p<0.001), after administration of Cr Pi more than L- carnitine. Conclusion: In this study we tried to compare a known drug (Chromium Picolinate) which is used a lot to improve obesity, with another drug (L- Carnitine) which is not well used for obesity or fatty liver, and discuss the effect of each of them. Each drug showed a great effect in different measurement which lead us that combination of both would have an amazing effect upon obese and fatty liver.

Keywords: Effect; Chromium; Piclonate; versus; L-Carnitine; High fat Diet; rat

#### 1. Introduction:

The global prevalence of overweight and obesity is increasing rapidly worldwide among all ages, where high dietary fat intake leads to dramatic complications and is associated with alterations in liver chemistry and structure<sup>1,2</sup>, hyperlipidemia<sup>3</sup>, fatty liver<sup>4</sup>, type II diabetes mellitus<sup>5</sup> and cardiovascular diseases<sup>6</sup>, increased risk of liver damage and hepatocellular degeneration.

Several pharmacological agents such as insulinsensitizing agents may be used to reduce or control the body weight and obesity. One of such agents, chromium (Cr) has been examined in some animal studies and clinical studies for its anti-obesity effects<sup>7</sup>. Cr is essential for the maintenance of normal metabolism of carbohydrate and lipids<sup>8</sup>. Inadequate amounts of Cr may result in improper functioning of the metabolic process and lead to a number of physiological disorders that increase risk for diabetes and cardiovascular diseases including elevated levels of glucose, triglycerides, total cholesterol, reduced HDLcholesterol and impaired immune function<sup>9,10,11</sup>.

Cr complexes have also been shown to reduce oxidative stress in diabetic rats 12,13

As known, L-Carnitine, a nutritional element, Carnitine is a quaternary ammonium compound which

is biosynthesized in the body from the essential amino acids lysine and methionine.<sup>14</sup>. It is supplemented in foods for healthy humans. It lowers lipid levels in the blood, and reduces high fat-induced obesity<sup>15,16</sup>. L-Carnitine is involved in long-chain fatty acids transporting from cytosol to the mitochondria matrix<sup>17</sup>, which is required for facilitating lipid metabolism and reducing the storage oflong-chain fatty acids in adipose. It is found in animal products like meat, fish, poultry, and milk are the best sources, In general, the redder the meat, the higher its carnitine content while dairy products contain little fraction of it.<sup>18</sup>L-Carnitine supplementation could prevent irregular feeding-induced lipid metabolism disorder. However, whether L-Carnitine may affect the disorder of circadian rhythm and lipid metabolism of mice subjected to prolonged circadian disruption is still not reported<sup>19</sup>. Carnitine homeostasis reflects the balance among absorption from the diet, endogenous biosynthesis, and efficient renal reabsorption<sup>20</sup>. In general, L-carnitine is not required for short- and medium-chain fatty acids to enter the mitochondrial matrix as described before, but is necessary for longchain fatty acids to do so.<sup>21</sup>

As a strong relationship exists between Body mass Index (BMI) and all-cause mortalityhas been

founded<sup>22</sup>. Obviously the need for natural supplements to decrease weight and help correction of some of complication became a very strong world need.<sup>23</sup>Which encourage us to study and assess the effect of organic chromium Piclonate and L- carnitine on rats feed on high fat diet with increased liver enzymes, cholesterol and triglycerides.

# 2. Materials and Methods

# Animals and diets

Male albino rats (n = 60, 4 weeks old) weighing 120-150 g were purchased from Pharos University Laboratory Animal Research Center (Alex, Egypt). Control group (n=20), Group I (n=20), and Group II (n=20). All procedures involving rats were conducted in strict compliance with relevant laws of Animal Welfare.

The animals were housed at the temperature of  $22 \pm 2^{\circ}$ C, humidity of  $55 \pm 5\%$ , and with a 12/12 h light/dark cycle throughout the experiment. The experiment was conducted under the protocol approved by the Pharos University.

Rats were fed standard diet (12% of calories as fat) or high fat diet (HFD, 40% of calories as fat). During the animal experimentation, rats in the treatment group I were supplemented with L-Carnitine (Mepaco-Medifood), group II were supplemented with Chromium Picolinate (Mepaco-Medifood) viadrinking water. Ingredients and chemical composition of the basal (control) diet are shown in (Table 1). The diets were stored at 4°C cold chamber.

# Experimental Design

After 1 week of adaptation period, the rats were randomly divided into three groups as (i) control group: rats were fed a standard diet (12% of calories as fat); (ii) Group I: L- carnitine group and group II: Chromium Picolinate (Cr Pi) group, both groups of rats were fed a high-fat diet (40% of calories as fat) first (according to table 1) for 60 days.

Table (1): Ingredient	and nutrient	composition	of
the diets <sup>24</sup>			

Ingredients (g/kg)	Normal Diet High	Fat Diet (HFD)		
Casein	200.0	200.0		
Starch	615.0	145.0		
Sucrose	-	150.0		
Beef tallow -	80.0	-		
Corn oil	•	400.0		
Cellulse	50.0	50.0		
Vitamin -Mineral Premix1	50.0	50.0		
DL-M ethionine	3.0	3.0		
Choline chloride	2.0	2.0		

Vitamin-mineral premix provides the following all-trans-retinylnacetate, 1.8 (per kg): mg; cholecalciferol, 0.025 mg; all-rac-a-tocopherol acetate, 12,5 mg; menadione (menadione sodium bisulfate), 1.1 mg; riboflavin, 4.4 mg; thiamine (thiamine mononitrate), 1.1 mg; vitamin B-6, 2.2 mg; niacin, 35 mg; Ca-pantothenate, 10 mg; vitamin B-12, 0.02 mg; folic acid, 0.55 mg; d-biotin, 0.1 mg. manganese (from manganese oxide), 40 mg; iron (from iron sulfate),12.5 mg; zinc (from zinc oxide), 25 mg; copper (from copper sulfate), 3.5 mg; iodine (from potassiumiodide), 0.3 mg; selenium (from sodium selenite), 0.15 mg; choline chloride, 175 mg.<sup>25</sup>(23).

After the routine analysis showed elevation in liver enzymes and high lipid profile, L- carnitine group: rats were received L- carnitine; which was dissolved in water and administered according to (table 2) Cr Pi group: was dissolved in water and administered according to (table 2) for 60 days.

Table	(2):	Drug	and	doses	
	(-/-	~ ~ ~ ~ ~	****		

Group I	Group II
L- carnitine daily dose	hromium Picolinatedaily dose
350mg/1mlw ater	24.85m g/1m1 water

# Laboratory Analyses

For the measurement of biochemical markers, samples were taken from the retro-orbital puncture under light ether anesthesia. Blood samples were centrifuged at 3000 g for 10 min and serum was separated. Fasting glucose concentrations, lipid profile, liver function were determined.

# Statistical analysis of the data

Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). The Kolmogorov-Smirnov and Shapiro wilk tests were used to verify the normality of distribution of variables, ANOVA was used for comparing the different studied groups and followed by Post Hoc test (Tukey) for pairwise comparison for normally distributed quantitative variables while Paired t-test was assessed for comparison between different periods. Kruskal Wallis test was used to compare different groups for abnormally distributed quantitative variables and followed by Post Hoc test (Dunn-Bonferroni) for pairwise comparison, While Wilcoxon signed ranks test was assessed for comparison between different periods. Significance of the obtained results was judged at the 5% level.




	Table (3):	Comparison betw	een the two studi	ied groups accord	ling to differen	it paramete	ers
	Control	Group I Group II		Group II			
		Before	After	Before	After	<b>p</b> 1	<b>p</b> <sub>2</sub>
	( <b>n</b> = 30)	(n = 30)	(n = 30)	(n = 30)	(n = 30)		
FBS	83.6±8.4	104.4±4.6	95.4±5.5 <sup>**</sup>	105.1±3.7	84.3±3.7"		*
<b>p</b> 3		<0.001	<0.001	< 0.001	0.891	0.873	<0.001
Urea	42.0±1.8	42.0±1.8	42.0±2.0	47.3±2.6	45.8±2.6 <sup>#</sup>		
p <sub>3</sub>		0.998	1.000	< 0.001*	<0.001*	<0.001*	<0.001*
Creat	1.0(0.8–1.0)	1.0(0.8-1.0)	1.0(0.8-1.1)	1.0(0.9-1.1)	1.0(0.9–1.1)		
<b>P</b> 3		1.000	0.486	$0.001^{*}$	0.003*	0.001*	<0.001*
p3 ALT	65.5±4.1	100.6±3.2	$94.8 \pm 3.6^{\#}$	104.7±4.1	$82.8\pm3.7^{\#}$		
D3		<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	<0.001*
p3 AST	83.3±4.9	173.3±7.4	$157.0\pm4.4^{\#}$	189.9±3.4	$159.0 \pm 4.6^{\#}$		
<b>p</b> 3		< 0.001*	<0.001*	<0.001*	<0.001*	<0.001*	0.211
p3 Ch	172.9±15.4	307.4±7.2	302.5±18.1	328.3±14.9	$303.7 \pm 10.9^{\#}$		
<b>P</b> <sub>3</sub>		< 0.001*	<0.001*	<0.001*	<0.001*	<0.001*	0.946
TG	82.0(70.0-94.0)	125(115-145)	$118(100-128)^{\#}$	125(115-145)	98(90-118) <sup>#</sup>		
D3		< 0.001*	<0.001*	< 0.001*	<0.001*	1.000	<0.001*
p3 HDL	38.8±3.3	32.3±1.7	$34.3\pm2.8^{\#}$	32.4±1.7	$37.2\pm2.2^{\#}$		
D3		<0.001*	<0.001*	<0.001*	0.067	0.985	<0.001*
p3 LDL	117.7±15.5	249.7±8.2	245.2±18.2	270.5±15.6	$246.5 \pm 11.7^{\#}$		
<b>p</b> 3		<0.001*	<0.001*	<0.001*	<0.001*	<0.001*	0.940

Normally quantitative data was expressed in mean  $\pm$  SD, not normally distributed data was expressed in median (Min. - Max.)

#: Statistically significant between before and after in each group, p<sub>1</sub>: p value for comparing between Group I and Group II before


 $p_2$ : p value for comparing between Group I and Group II after,  $p_3$ : p value for comparing between control and each other groups

\*: Statistically significant at  $p \le 0.05$ 



#: Statistically significant between before and after in each group


\*: comparing between control and each other groups Figure (1): Comparison between the two studied groups according to Cholesterol



#: Statistically significant between before and after in each group

\*: comparing between control and each other groups Figure (2): Comparison between the two studied groups according to TG





#: Statistically significant between before and after in each group

\*: comparing between control and each other groups Figure (3): Comparison between the two studied groups according to LDL

# 3. Results:

Analytical results between three groups were represented in table (3). Feeding rats with high-fat diets resulted in the slightly increasing body weight gain and the significantly increasing body mass/body length ratio (by 10%).

As for Fasting blood sugar (FBS) there was statically significantly lower values (SD= $84.3\pm3.7$ , P< 0.001) between group II Chromium group (Cr gp) over group I (L- carnitine group) after administration of drug.

Regarding Hepatic enzymes; alanine aminotransferease (ALT showed a statistically significantly lower values (P< 0.001) between Group Π (82.8±3.7) over Group I (94.8±3.6) after administration of drugs, While AST showed a statistically significantly lower values (P< 0.001) between both Group I, Group II comparing before and after drug within the same group, but did not show statistically difference between groups after administration of drugs.

As for Total Cholesterol (Ch) there was a statistically significant decreased values between both groups and Control group, with significant lower value in group II after administration of chromium Picolinate  $(303\pm10.9, p<0.001)$ .

Regarding Triglycerides (TG), Cr Pigp showed a great lowering effect than the L- Carnitinegp as there was a statistically significant lower values, as mean of Cr Pi gp II was [98(90-118), p < 0.001] while mean for L- Carnitine gp I [118(100-128)].

As for low density lipids (LDL) Also Cr Pigp showed a statistically significant lowering effect after administration of the drug [246.5 $\pm$ 11.7], (p<0.001), although there was a decreased difference between groups after administration of drugs, it was not statistically significant (P=0.940) between both groups after administration of drugs.

### 4. Discussion:

The prevalence of Fatty liver disease has been increasing worldwide and its spectrum ranges from simple steatosis, non-alcoholic NASH, advanced fibrosis and cirrhosis.<sup>26</sup> A number of studies both on diabetic animals and diabetic patients reported that CrPi supplementation may be beneficial, as evidenced by decreased blood glucose, glycosylated hemoglobin, and cholesterol values or decreased insulin requirements after Cr Pi supplementation.<sup>27</sup>On the other hand, there are also clinical trials showing that supplementary CrPi did not improve significantly blood biochemistry indices  $^{28}$ . While the essentiality of chromium for humans has been recently questioned by researchers; the pharmacological dosages of this element improved insulin sensitivity in experimental animals and diabetic subjects<sup>29</sup>, which need more investigation to fill the gap between experimental and application to human beings.

Mitochondrial abnormality is well documented in Non-alcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease (NAFLD) and a suggested target for treatment<sup>30</sup> therefore the choice of L- carnitine was made to improve the oxidation of fatty acid deposited in liver which was documented in several studies to improve mitochondrial function<sup>31</sup> and biosynthesis<sup>32</sup>.

In our study Chromium Pollinate showed significantly and statistically decreased in FBS. Which agree with the results done by Jaroslav Racek et al done on diabetic patients receiving chromium FBS levels decreased significantly during the first supplementation period (period B, 100  $\mu$ g of chromium daily); doubling the chromium dose in period C led to a further decrease of FPG level; however, this decrease was not statistically significant<sup>33</sup>.

Chromium Pollinate also showed significantly and statistically decreased level of both AST and ALT. This is also in agreement with Doddigarla Z et al, as they deduced that chromium Pollinate showed a significant effect on rat fed on it for 8 weeks and was on high carbohydrate diet where total cholesterol, triglyceride significantly decreased while HDL increased, also when chromium combined with melatonin showed even better results. This was documented with histological changes in different groups.<sup>34</sup>

As for L-carnitine in the present study there were significantly and statistically decreased in the level of FBS, hepatic enzymes (AST and Alt), and lipid profile. this agree with Ji Cheol Bae et al<sup>35</sup>, where Treatment with Carnitine-orotate complex improves serum to the normal range, a significant decrease from baseline in HbA1c, However, no significant changes



were seen in fasting glucose, HOMA-IR, HOMA-B, lipid profile.

This is in agreement with Xiaoxian Xie et al; who feed mice with L-Carnitine where they was subjected to chronic jet-lag, the serum GPT and GOT activities were decreased as compared with those in the jetlag group that were not on L Carnitine, but they did not exhibit obvious differences in the concentrations of serum total cholesterol and TC/HDL-C ratio among different groups. More importantly, quantitative real-time polymerase chain reaction (qRT-PCR) analysis indicated that L-Carnitine supplementation would effectively counteract the negative alterations in gene expression which related to lipid metabolism and circadian rhythm.36

Wu T et al also deduced that L-Carnitine supplementation showed reduced obesity caused by high-fat diet and irregular feeding-induced obesity, and it is beneficial for lowering blood and hepatic lipid levels namely GPT, GOT and TG.<sup>37</sup>

### **Conclusion:**

As the number of patients with a fatty liver is increasing and studies with the long-term objective of improving the fatty liver is strongly needed, therefore new therapies must be developed to combat such illness. Again this emphasizes the importance of such research to encourage more researchers to combine more pharmacological items to solve such an issue.

In this study we tried to compare a known drug (Chromium Picolinate) which is used a lot to improve obesity, with another drug (L- Carnitine) which is not well used for obesity or fatty liver. We recommend strongly associating both drugs with each other using different doses in Vivo study, which may ultimately assist clinicians in controlling fatty liver and hyperglycemia.

### **References:**

- Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT: High-fat diets promote insulin resistance through cytokine gene expression in growing female rats. J Nutr Biochem 2007; 19:505-13.
- Ribeiro MC, Barbosa NB, de Almeida TM, Parcianello LM, Perottoni J, de Avila DS, Rocha JB: High-fat diet and hydrochlorothiazide increase oxidative stress in brain of rats. Cell Biochem Funct 2009; 27:473-8.
- Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, et al: Interdisciplinary European guidelines on surgery for severe obesity. Rozhl Chir 2008; 87:468-76.

- Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K: Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007; 22:2009-2014. Tuzcu et al.
- 5. Pagotto U, Vanuzzo D, Vicennati V, Pasquali RG: Pharmacological therapy of obesity. G Ital Cardiol (Rome) 2008;9:83-93.
- 6. Lavie CJ, Artham SM, Milani RV, Ventura HO: The obesity paradox: impact of obesity on the prevalence prognosis of cardiovascular diseases. Postgrad Med 2008;120: 34-41.
- Pittler MH, Stevinson C, Ernst E: Chromium picolinate for reducing body weight: Metaanalysis of randomized trials. Int J Obesity 2003;27:522-9.
- 8. Mertz W: Chromium in human nutrition: a review. J Nutr 1993;123:626-33.
- 9. Anderson RA: Chromium, glucose tolerance, and diabetes. Biol Trace Elem Res 1992; 32:19-24.
- 10. <sup>1</sup>Anderson RA: Chromium in the prevention and control of diabetes. Diabetes Metab 2000;26:22-7.
- 11. Mozaffari MS, Abdelsayed R, Liu JY, Wimborne H, El-Remessy A, El- Marakby: Effects of chromium picolinate on glycemic control and kidney of the obese Zucker rat. Nutr Metab 2009; 10:6-51.
- Preuss HG, Grojec PL, Lieberman S, Anderson RA: Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Clin Nephrol 1997; 47:325-30.
- Sahin K, Onderci M, Tuzcu M, Ustundag B, Cikim G, Ozercan IH, Sriramoju V, Juturu V, Komorowski JR: Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metab Clin Exp 2007; 56:1233-40.
- Charles Hoppel: The role of carnitine in normal and altered fatty acid metabolism. AKJD 2003; 41:4, S4–S12. DOI: 10.1016/S0272-6386(03)00112-4.
- 15. Kim YJ, Kim KY, Kim MS, Lee JH, Lee KP, Park T: A mixture of the aqueous extract of Garcinia cambogia, soypeptide and L-carnitine reduces the accumulation of visceral fat mass in rats rendered obese by a high fat diet. Genes Nutr 2008;2: 353-8.
- LIU L, ZHANG D, WANG M, FAN C, ZHOU F, WANG S, KONG L: The adverse effects of long-term l-carnitine supplementation on liver and kidney function in rats. Hum Exp Toxicol 2015;34: 1148-61.



- Marcovina Sm, Sirtori C, Peracino A, Gheorghiad E M, Borum P, Remuzzi G, Ardehali H: Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res 2103;161: 73-84.
- 18. Carnitine: lessons from one hundred years of research. Ann NY Acad Sci 2004;1033:ix-xi.
- Wu T, Guo A, Shu Q, Qi Y, Kong Y, Sun Z, Sun S, Fu Z: L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. Gene 2015;554: 148-154.
- 20. Rebouche CJ: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004; 1033:30–41.
- <sup>1</sup>Koichi Fujisawa, Taro Takami, Aya Matsuzaki, et al: Evaluation of the effects of L-carnitine on medaka (Oryziaslatipes) fatty liver. Scientific Reports 7: 2749 doi:10.1038/s41598-017-02924-5 w.
- 22. Calle EE, Thun MJ, Petrelli JM, et al: Bodymass index and mortality in a prospective cohort of U.S. adults. NEJM 1999;341:1097–1105.
- 23. Yuka yazaki, Zubaidafaridi, Yingying ma: A Pilot Study of Chromium Picolinate for weight loss. The Journal of Alternative and Complementary medicine. 2010; 16:291–9. doi: 10.1089=acm.2009.0286.
- 24. Mehmet Tuzcu, Nurhan Sahin, Cemal Orhan, et al. Impact of chromium histidinate onhigh fat diet induced obesity in rats. Nutrition & Metabolism 2011, 8:28.
- 25. Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, et al: Interdisciplinary European guidelines on surgery for severe obesity. Rozhl Chir 2008; 87:468-476.
- 26. Pulsombat A, Warodomwichit D, Sornmayura P, et al Adipokines in non-alcoholic fatty liver disease. Thai J Gastroenterol 2014; 15:22.
- 27. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741–51.
- Król E, Krejpcio Z, Byks H, Bogdański P, Pupek-Musialik D. Effects of chromium brewer's yeast supplementation on body mass, blood carbohydrates, and lipids and minerals in type 2 diabetic patients. Biol Trace Elem Res 2011;143(2):726–37.

- Ewelina Król & Zbigniew Krejpcio & Katarzyna Iwanik. Supplementary Chromium (III) Propionate Complex Does Not Protect Against Insulin Resistance in High-Fat-Fed Rats. Biol Trace Elem Res 2014; 157:147–155.DOI 10.1007/s12011-013-9877-3.
- Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008;14:193–9.
- Virmani A, Gaetani F, Binienda Z, Xu A, Duhart H, Ali SF. Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine. Ann N Y Acad Sci 2004;1025:267–73.
- Hota KB, Hota SK, Chaurasia OP, Singh SB. Acetyl-L-carnitine-mediated neuroprotection during hypoxia is attributed to ERK1/2-Nrf2regulated mitochondrial biosynthesis. Hippocampus 2012;22:723–36.
- 33. Aroslav Racek & C. D. Sindberg & S. Moesgaard & Josef Mainz & Jaroslav Fabry & Luděk Müller & Katarína Rácová. Effect of Chromium-Enriched Yeast on Fasting Plasma Glucose, Glycated Haemoglobin and Serum Lipid Levels in Patients with Type 2 Diabetes Mellitus Treated with Insulin. Biol Trace Elem Res 2013;155:1–4.DOI 10.1007/s12011-013-9758-9.
- 34. Doddigarla Z, Parwez I, Abidi S2and Ahmad J. Effect of Melatonin and Chromium Picolinate Administration to High Carbohydrate Diet-Fed Male Wistar Rats. J Mol Genet Med 2017; 11:1 doi: 10.4172/1747-0862.1000245.
- 35. Ji Cheol Bae, Won Young Lee, Kun Ho Yoon, et al. Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. Diabetes Care 2015;38:1245– 1252. DOI: 10.2337/dc14-2852.
- 36. Xiaoxian XIE, Anqi GUO, Tao WU. Preventive Effect of L-Carnitine on the Disorder of Lipid Metabolism and Circadian Clock of Mice Subjected to Chronic Jet-Lag. Physiol. Res. 2017;66: 801-10.
- 37. Wu T<sup>1</sup>, Guo A<sup>1</sup>, Shu Q. L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. <u>Gene</u>. 2015; 554(2):148-54.